Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malaria is a leading cause of death and illness around the world. Over 200 million cases are reported every year, and more than 400 000 people die. More than 90% of cases are reported in sub-Saharan Africa. Scientists have spent decades searching for an effective vaccine. Hence the recent excitement when Malawi’s government announced it had launched a pilot programme for the world’s first malaria vaccine, RTS,S (also known as Mosquirix©), produced by the pharmaceutical company, GSK. It’s the first vaccine to demonstrate significant reduction in malaria in children. The Conversation Africa’s Ina Skosana asked immunologist Faith Osier about RTS,S.

The Conversation logo

Similar stories

Celebrating Women and Girls in Science

Women have made significant contribution in research despite the numerous challenges they face. To celebrate the women and girls in science we asked some women at KEMRI Wellcome Trust Research programme to share their journey in research, their achievements, and a word of advice to fellow women in science.

VAnguard Launch

KWTRP hosted the launch of the VAnguard research project. The NIHR Funded Project Builds Knowledge-base on Factors Influencing Vaccine Impact among Communities in Kenya and Uganda. The project aims to strengthen collaborations between national and international stakeholders in the identification of social and biological factors that impair vaccine impact in African communities, to develop integrated strategies and recommendations to optimize vaccine impact, and to contribute to health equity in Africa. The launch concurrently took place in Kenya and Uganda from 28th – 30th November 2022.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

Quality of care, health workers’ well-being and COVID-19

Nurses are central players in the provision of quality health care globally. Although neonatal units have not been at the epicenter of the current COVID-19 pandemic, challenges have also been raised for neonatal nurses. KWTRP share their COVID-19 related experiences and challenges, highlight strategies they used to manage the challenges and show how elements of the communication skills and emotional competence course helped them cope.

High prevalence of antibodies against COVID-19 within the general population: Evidence from Nairobi and Kilifi

By May 2022, 69% of individuals residing within the Kilifi Health and Demographic System (HDSS) and 91% residing within the Nairobi Urban HDSS had evidence of an immune response to COVID-19 resulting from natural infection and/or vaccination, i.e., anti-spike IgG antibodies.

Taking relationships seriously

Community Engagement (CE) is a critical aspect of health research because of its potential to make research more ethical, relevant, and well implemented. Many research programmes now aim to incorporate CE activities at all stages of their work. This KWTRP brief summarises key findings from a malaria trials, and provides an illustration of how CE works more generally. It highlights facilitators and challenges to engagement, and the ethical issues that are particularly relevant in LMIC settings with under resourced health systems.